CPIX insider buys in July under 10b5-1 plan; holdings 43,676 shares

Rhea-AI Filing Summary

James Jones, identified as a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of systematic purchases of the issuer's common stock during July 2025. The table discloses multiple acquisitions executed across July 1–31, 2025, with reported transaction prices ranging from $3.05 to $3.82 per share. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

The Form shows the reporting person’s beneficial ownership rising through the month, culminating at 43,676 shares following the July 31, 2025 purchase. The filing was signed by an attorney-in-fact on behalf of James Jones and discloses the transactions as purchases under the Section 16 reporting requirements.

Insights

Financial Analyst

TL;DR Insider purchases under a 10b5-1 plan increased holdings to 43,676 shares; trades are systematic and small relative to typical market-moving insider activity.

The reported transactions occurred daily across July 1–31, 2025, at prices between $3.05 and $3.82. The explicit mention of a Rule 10b5-1 plan adopted on November 14, 2024, indicates these were pre-planned purchases, which reduces the informational content of each trade for timing or sentiment inference. Aggregating the disclosed beneficial ownership figures shows an ending position of 43,676 shares. From an investment-materiality perspective, these routine plan-driven purchases are neutral because they do not represent a large, concentrated acquisition disclosed to materially change ownership.

Corporate Governance Expert

TL;DR Disclosure aligns with Section 16 reporting and 10b5-1 plan use; filings and attorney-in-fact signature indicate procedural compliance.

The Form 4 details multiple purchase transactions reported under the issuer's insider reporting regime and explicitly states the trades were automatic under a Rule 10b5-1 plan adopted November 14, 2024. The presence of an attorney-in-fact signature reflects permitted execution practices. The disclosure of transaction dates, prices, and the post-transaction beneficial ownership level (43,676 shares) meets the core transparency requirements for insider trading reports. Governance implications are procedural compliance rather than a material governance change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones James

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		P	V	16(1)	A	$3.56	43,352	D
Common Stock	07/02/2025		P	V	16(1)	A	$3.52	43,368	D
Common Stock	07/03/2025		P	V	16(1)	A	$3.31	43,384	D
Common Stock	07/07/2025		P	V	16(1)	A	$3.23	43,400	D
Common Stock	07/08/2025		P	V	16(1)	A	$3.06	43,416	D
Common Stock	07/09/2025		P	V	16(1)	A	$3.05	43,432	D
Common Stock	07/10/2025		P	V	16(1)	A	$3.2	43,448	D
Common Stock	07/11/2025		P	V	16(1)	A	$3.21	43,464	D
Common Stock	07/14/2025		P	V	16(1)	A	$3.46	43,480	D
Common Stock	07/15/2025		P	V	16(1)	A	$3.45	43,496	D
Common Stock	07/16/2025		P	V	16(1)	A	$3.79	43,512	D
Common Stock	07/17/2025		P	V	16(1)	A	$3.82	43,528	D
Common Stock	07/18/2025		P	V	16(1)	A	$3.59	43,544	D
Common Stock	07/21/2025		P	V	16(1)	A	$3.45	43,560	D
Common Stock	07/22/2025		P	V	16(1)	A	$3.47	43,576	D
Common Stock	07/23/2025		P	V	16(1)	A	$3.54	43,592	D
Common Stock	07/24/2025		P	V	16(1)	A	$3.55	43,608	D
Common Stock	07/25/2025		P	V	16(1)	A	$3.37	43,624	D
Common Stock	07/28/2025		P	V	13(1)	A	$3.47	43,637	D
Common Stock	07/29/2025		P	V	13(1)	A	$3.33	43,650	D
Common Stock	07/30/2025		P	V	13(1)	A	$3.55	43,663	D
Common Stock	07/31/2025		P	V	13(1)	A	$3.5	43,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	James Jones by /s/ John Hamm as attorney-in-fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 and what is their relationship to CPIX?

James Jones filed the Form 4 and is identified in the filing as a director of Cumberland Pharmaceuticals Inc. (CPIX).

When were the reported transactions executed and under what plan?

The purchases were executed across July 1–31, 2025 and the filing states they occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

What prices were paid in the July purchases?

The reported transaction prices range from $3.05 to $3.82 per share during July 2025 as shown in the table.

How many shares did the reporting person beneficially own after the last disclosed transaction?

Following the July 31, 2025 purchase, the filing reports total beneficial ownership of 43,676 shares.

Does the filing indicate whether the transactions were purchases or sales?

The transactions in Table I are identified as purchases (transaction code indicating acquisition) executed under the 10b5-1 plan.